INMB - INmune Bio Inc

INMB - INmune Bio Inc

https://www.inmunebio.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

INmune Bio ( INMB ) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Commentary • 6 days, 18 hours ago • score: 0.28

INmune Bio (INMB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

GlobeNewswire • 1 month, 2 weeks ago • score: -0.18

Management to host conference call and webcast at 4:30 pm ET on that day ...

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday - INmune Bio ( NASDAQ:INMB )

Benzinga • 2 months, 1 week ago • score: 0.27

Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge. What Happened: On Saturday, in a post on X, Shkreli forecasted a potential 90% drop in the shares of biotech startup, Inmune Bio Inc.

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday - INmune Bio ( NASDAQ:INMB )

Benzinga • 2 months, 1 week ago • score: 0.27

Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge. What Happened: On Saturday, in a post on X, Shkreli forecasted a potential 90% drop in the shares of biotech startup, Inmune Bio Inc.

This Textron Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Lineage ( NASDAQ:LINE ) , INmune Bio ( NASDAQ:INMB )

Benzinga • 2 months, 1 week ago • score: 0.24

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. TD Securities analyst Andrew Charles downgraded the rating for Sweetgreen, Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease, and nonalcoholic steatohepatitis. The company is headquartered in La Jolla, California.

52W High

$10.50

52W Low

$1.86

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.04

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-5.31

EV/Revenue (<3 favorable)

378.37

P/S (TTM) (<3 favorable)

1036.83

P/B (<3 favorable)

1.80

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

24.61%

Institutions (25–75% balanced)

21.21%

Shares Outstanding

26,585,300

Float

18,722,900

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

50,000

Gross Profit (TTM)

50,000

EPS (TTM)

-2.49

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-794.30%

ROE (TTM) (>15% strong)

-1.68%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

2.57

Momentum

Bearish momentum

Value

-0.3095

Previous

-0.3165

Trend

Rising

Signal Cross

No cross

As of

Sep. 05, 2025